H6D0:F:F-Haleon PLC (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 4.484

Change

-0.08 (-1.84)%

Market Cap

USD 41.60B

Volume

850.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRKC:F MERCK KGAA NAM.SP.ADR

-0.60 (-1.95%)

USD 68.55B
MRK:F Merck & Company Inc

-1.65 (-1.08%)

USD 67.36B
RDDA:F Dr. Reddy's Laboratories Limit..

-2.00 (-2.86%)

USD 59.15B
TKDA:F Takeda Pharmaceutical Company ..

+0.20 (+1.61%)

USD 41.17B
H6D:F Haleon PLC

-0.10 (-1.12%)

USD 40.82B
TEV:F Teva Pharmaceutical Industries..

+0.20 (+1.18%)

USD 19.32B
3KY:F HANSOH PHARMAC. HD-00001

-0.26 (-11.11%)

USD 15.54B
SH0:F Shionogi & Co. Ltd

-1.30 (-9.35%)

USD 10.96B
NB3:F Neurocrine Biosciences Inc

+0.80 (+0.75%)

USD 10.71B
0C8:F Catalent Inc

-0.18 (-0.33%)

USD 9.81B

ETFs Containing H6D0:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.76% 69% C- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.76% 69% C- 74% C
Trailing 12 Months  
Capital Gain 18.75% 64% D 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.75% 64% D 60% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 5.86% 69% C- 59% D-
Dividend Return 6.25% 62% D 53% F
Total Return 0.40% 18% F 16% F
Risk Return Profile  
Volatility (Standard Deviation) 9.39% 96% N/A 90% A-
Risk Adjusted Return 66.58% 86% B+ 80% B-
Market Capitalization 41.60B 98% N/A 95% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.